Ilumivu's digital health platform has been used to monitor numerous diseases and conditions, including autism, Alzheimer’s, heart/blood pressure/strokes and cardiovascular diseases, cancer, chronic lung disease including COPD, dementia, epilepsy, mental and behavioral issues, traumatic brain injury, suicidal tendency, and trauma/PTSD. The company's patient-centered platform captures rich, multimodal behavioral data streams through user engagement, enabling families struggling with autism to effectively measure outcomes and track the process of change. Founded in 2009, ilumivu has a pedigree in research in multiple disease areas at over 100 leading research universities and health systems.